Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients

Journal of Infection

Volumn 54, Issue 6, 2007, Pages 597-602

  Chinello, Pierangelo ^a   Lisena, Francesco P ^a   Angeletti, Claudio ^a   Boumis, Evangelo ^a   Papetti, Federica ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Efavirenz; HIV; Nelfinavir; QT interval; Zidovudine

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PROTEINASE INHIBITOR; PYRIMETHAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR;

AGED; BENZOXAZINES; CASE-CONTROL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; ZIDOVUDINE;

EID: 34248344268     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.11.001     Document Type: Article

References (28)

1. Kocheril A.G., Bokhari S.A.J., Batsford W.P., and Sinusas A.J. Long QTc and torsades de pointes in human immunodeficiency virus disease. PACE 20 (1997) 2810-2816
2. Sani M.U., and Okeahialam B.N. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 97 (2005) 1657-1661
3. Nordin C., Kohli A., Beca S., Zaharia V., Grant T., Leider J., et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 39 (2006) 199-205
4. Eisenhauer M.D., Eliasson A.H., Taylor A.J., Coyne Jr. P.E., and Wortham D.C. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105 (1994) 389-395
5. von Seidlen L., Jaffar S., and Greenwood B. Prolongation of QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 56 (1997) 494-497
6. Lopez J.A., Harold J.G., Rosenthal M.C., Oseran D.S., Schapira J.N., and Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59 (1987) 376-377
7. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., Guma JR., et al. QT prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 92 (2003) 995-997
8. Vallejo Camazon N., Rodriguez Pardo D., Sanchez Hidalgo A., Tornos Mas M.P., Ribera E., and Soler Soler J. Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection. Rev Esp Cardiol 55 (2002) 878-881
9. Flanagan MC., Mitchell ES., and Haigney MC. Ciprofloxacin-induced torsade de pointes. Int J Cardiol 113 (2006) 239-241
10. Prabhakar M., and Krahn A.D. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm 1 (2004) 624-626
11. Castillo R., Pedalino R.P., El-Sherif N., and Turitto G. Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia. Ann Pharmacother 36 (2002) 1006-1008
12. Anson B.D., Weaver J.G., Ackerman M.J., Akinsete O., Henry K., January C.T., et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 365 (2005) 682-686
13. Villa A., Foresti V., and Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 5 (1995) 48-52
14. The Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 106 (2002) 3143-3421
15. Saitz R. Unhealthy alcohol use. N Engl J Med 352 (2005) 596-607
16. Al-Khatib S.M., LaPointe N.M., Kramer J.M., and Califf R.M. What clinicians should know about the QT interval. JAMA 289 (2003) 2120-2127
17. Schouten E.G., Dekker J.M., Meppelink P., Kok F.J., Vandenbroucke J.P., and Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84 (1991) 1862-1865
18. Moss A.J. Measurement of the QT interval and the risk associated with QTc in interval prolongation: a review. Am J Cardiol 72 (1993) 23B-25B
19. Lorsheyd A., de Lange D.W., Hijmering M.L., Cramer M.J.M., and van de Wiel A. PR and QTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals. Neth J Med 63 (2005) 59-63
20. Fantoni M., Autore C., and Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann N Y Acad Sci 946 (2001) 179-199
21. Sticherling C., Schaer B.A., Ammann P., Maeder M., and Osswald S. Methadone-induced torsade de pointes tachycardias. Swiss Med Wkly 135 (2005) 282-285
22. Pearson E.C., and Woosley R.L. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 14 (2005) 747-753
23. Ehret G.B., Voide C., Gex-Fabry M., Chabert J., Shah D., Broers B., et al. Drug-induced long QT syndrome in injection drug users receiving methadone. Arch Intern Med 166 (2006) 1280-1287
24. Krantz M.J., and Mehler P.S. QTc prolongation: methadone's efficacy-safety paradox. Lancet 368 (2006) 556-557
25. Krantz M.J., Garcia J.A., and Mehler P.S. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 25 (2005) 611-614
26. Szabados E., Fisher G.M., Toth K., Csete B., Nemeti B., Trombitas K., et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med 26 (1999) 309-317
27. Bonnemeier H., Wiegand U.K., Braasch W., Brandes A., Richardt G., and Potratz J. Circadian profile of QT interval and QT interval variability in 172 healthy volunteers. Pacing Clin Electrophysiol 26 (2003) 377-382
28. Piotrovsky V. Pharmacokinetic-pharmacodynamic modelling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 7 (2005) E609-E624